Professor Lancet is a medical oncologist at the H. Lee Moffitt Cancer Center whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukemias.

Professor Lancet was an investigator on PTX’s earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.